TGF-β in cancer and other diseases

Future Oncology

Volumn 2, Issue 2, 2006, Pages 185-189

  Neil, Jason R ^a   Galliher, Amy J ^a   Schiemann, William P ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AP 12009; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLOOXYGENASE 2 INHIBITOR; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GC 1008; LY 2157299; MONOCLONAL ANTIBODY ID11; MYC PROTEIN; PERVANADATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BENIGN SKIN TUMOR; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER GENETICS; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CHEMOTAXIS; COLITIS; COLON CANCER; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME INACTIVATION; FAMILIAL COLON POLYPOSIS; GENE OVEREXPRESSION; GLIOMA; HUMAN; HYPERPLASIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LUNG TUMOR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE RAS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646451248     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.2.185     Document Type: Conference Paper

References (15)

1. Moses HL, Branum EL, Proper JA, Robinson RA: Transforming growth factor production by chemically transformed cells. Cancer Res. 41, 2842-2848 (1981).
2. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl Acad. Sci. USA 78, 5339-5343 (1981).
3. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor β In human disease. N. Engl. J. Med. 342, 1350-1358 (2000).
4. Tang B, Vu M, Booker T et al.: TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 112, 1116-1124 (2003).
5. Mishra L, Derynck R, Mishra B: Transforming growth factor-β signaling in stem cells and cancer. Science 310, 68-71 (2005).
6. Seoane J, Le HV, Shen L, Anderson SA, Massague J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (2004).
7. Shull MM, Ormsby I, Kier AB et al.: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
8. Li MO, Wan YY, Sanjabi S. Robertson AK, Flavell RA: Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 4.1-4.48 (2006).
9. Letterio JJ: TGF-β signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene 24, 5701-5712 (2005).
10. Kirkbride KC, Ray BN, Blobe GC: Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem. Sci. 30, 611-621 (2005).
11. Blobe GC, Schiemann WP, Pepin MC et al.: Functional roles for the cytoplasmic domain of the type III transforming growth factor β receptor in regulating transforming growth factor β signaling. J. Biol. Chem. 276, 24627-24637 (2001).
12. Rifkin DB: Latent transforming growth factor-β (TGF-β) binding proteins: Orchestrators of TGF-β availability J. Biol. Chem. 280, 7409-7412 (2005).
13. Zanetti M, Braghetta P, Sabatelli P et al.: EMILIN- 1 deficiency Induces elastogenesis and vascular cell defects. Mol. Cell. Biol. 24, 638-650 (2004).
14. Albig AR, Schiemann WP: Fibulin-5 antagonizes vascular enclothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell. Biol. 23, 367-379 (2004).
15. Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF: Context-specific effects of fibulin-5 (DANCE/ EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-β and affects protein kinase cascades. J. Biol. Chem. 277, 27367-27377 (2002).